COMBINATION OF A SELECTIVE HISTONE DEACETYLASE 3 (HDAC3) INHIBITOR AND AN IMMUNOTHERAPY AGENT FOR THE TREATMENT OF CANCER
申请人:KDAc Therapeutics, Inc.
公开号:US20190216754A1
公开(公告)日:2019-07-18
Aspects of the disclosure relate to compositions, kits, and methods for the treatment of cancer that utilize a selective histonc deacetylase 3 (HDAC3) inhibitor. In some aspects, the compositions, kits, and methods relate to use of a selective HDAC3 inhibitor in combination with an immunotherapy agent (e.g., an immune checkpoint inhibitor).
COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS
申请人:BIOMARIN PHARMACEUTICAL INC.
公开号:US20160122290A1
公开(公告)日:2016-05-05
This invention relates to compounds of Formula (I) wherein Cy
1
, L
1
, Y, R
1
, L
2
, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions.
[EN] COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS<br/>[FR] COMPOSITIONS COMPRENANT DES DÉRIVÉS D'ACIDE 6-AMINOHEXANOÏQUE UTILISÉES COMME INHIBITEURS DE HDAC
申请人:REPLIGEN CORP
公开号:WO2010028192A1
公开(公告)日:2010-03-11
This invention relates to compounds of Formula (I) wherein Cy1, L1, Y, R1, L2, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions.